NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
Oteseconazole Capsules were found to be safe and more effective than fluconazole
The campaign seeks to raise awareness about hypertension while emphasising the significance of managing blood pressure for a healthier lifestyle
Need to harmonize traditional and modern medicine to combat alarming health problems
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
The company has secured 506 marketing approvals for its oncology products across 76 countries.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Subscribe To Our Newsletter & Stay Updated